Novo Nordisk A/S vs AT&T Inc. — how do they compare? Novo Nordisk A/S trades at $45.93 (market cap $207.85B), while AT&T Inc. trades at $24.4 (market cap $167.88B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (4.53%). Which is the better fit depends on your goals.
| NVO | T | |
|---|---|---|
Market Cap | $207.85B | $167.88B |
Sector | Health | Media |
52-Week High | $63.98 | $29.62 |
52-Week Low | $35.29 | $20.49 |
Enterprise Value | $222.55B | $313.20B |
Dividend Yield | 3.81% | 4.53% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →